Discovery

From Associated Press (July 6, 2010)

GEORGETOWN, Texas -- Molecular Templates said Tuesday it entered a cancer drug discovery and research deal with Eli Lilly & Co. unit ImClone Systems.

Under the deal, Molecular Templates will identify engineered toxin bodies against an undisclosed cancer target.

ImClone will conduct preclinical studies using the engineered toxin bodies to evaluate their potential.